View more on these topics

Seconds out for NDF

NDF Administration has introduced the second issue of the NDF higher income & growth plan, a guaranteed equity bond that is linked to the 10 largest stocks in the FTSE 100 index. These companies are Astrazeneca, Barclays, BP, Glaxo Wellcome, HBOS, HSBC, Lloyds TSB, Royal Bank of Scotland, Shell and Vodafone.

Investors have three options — annual income of 9 per cent, monthly income of 0.7 per cent or growth of 50 per cent. These rates are the same as offered by the first issue of the bond.

The return of the original capital plus income or growth is guaranteed if the final level of each stock is up to 20 per cent lower than the starting level. However, the return for income investors is less the income they have already taken.

If one stock is more than 20 per cent below its initial value, investors get 85 per cent of their capital. Two stocks below 85 per cent of their starting value gives a return of 65 per cent of the original capital. Three or more stocks more than 20 per cent below their initial starting levels gives annual income investors a return of 55 per cent of the original capital and monthly income investors 58 per cent of the original capital.

Eurolife’s investment plus plan is a similar bond that offers higher income and growth than NDF’s bond. It provides annual income of 10 per cent, monthly income of 0.8 per cent and a choice of 45 per cent growth or 65 per cent growth. Unlike NDF’s plan, it is linked to three indices, which spreads the risk across more stocks than NDF’s plan. Even if one stock falls by 21 per cent, this will impact on the overall return with NDF and this could make it unattractive for some investors.


Industry will be hurt by CP121

Open letter to David Severn, Head of polarisation review, FSA Should the proposals outlined in the CP121 come into being, I believe that this willdamage the financial services industry and infrastructure andconfuse consumers by over-complication.The FSA needs to understand the basics of the industry it is empowered to regulate.The vast majority of products offered by […]

Will IPA ever go to the ball?

What happened to the IPA? No, not the Institute for Prac-titioners in Advertising, which has its hands full at the mom-ent, and, no, not the brewery, whose beer is still being guzzled but the individual pensions account – New Labour&#39s next big idea for pensions after stakeholder.Despite drumrolls following on from a tortuous gestation, there […]

New director for Neville James

Tep market maker Neville James is boosting its trading team with the promotion of Karen Gill as director of the Tep marketing division.Gill has been with Neville James since 1996 and was previously genera manager of trading.Neville James managing director John Heller says: “Karen&#39s experience and proven track record will add to the company&#39s continuing […]

UnumProvident claims breakthrough with three-tier critical cover product

UnumProvident is looking to shake up the critical-illness cover market with an individual product which it claims could slash premiums by as much as 50 per cent.Elixia 123 has three tiers – life-threatening, disabling and traumatic – with premiums varying depending on the level of cover required.Policyholders can split the sum insured between the tiers […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment


    Why register with Money Marketing ?

    Providing trusted insight for professional advisers.  Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm